JPRN-jRCT2080221108未知1 期
Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate Treatment
适应症
试验速览
- 阶段
- 1 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Eligible patients are those who have rheumatoid arthritis according to the American Rheumatism Association 1987 revised criteria, who have used methotrexate for at least 12 weeks and have been on a stable dose, at least 7.5 mg/week, for no less than 8 weeks. Serum C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) values must be more than the upper limit of normal (ULN) at study entry.
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease (I8G-MC-LMDD)Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's DiseaseJPRN-jRCT2080223501Eli Lilly Japan K.K.
进行中（未招募）
不适用
Single-Dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in Patients with COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-010821-38-GBElevation Pharmaceuticals, Inc12
未知
1 期
Multiple-Dose, Dose-Escalation Study to EvaluateRheumatoid ArthritisJPRN-jRCT2080221342Eli Lilly Japan K.K.
已完成
1 期
A study in healthy subjects to see the effects of the test medicine ALKS 2680 in single and multi-dose regimePhase 1 drug studyNervous System DiseasesISRCTN98204977Alkermes (United States)147
已完成
1 期
K757 and K833 multiple-dose study in healthy subjectsHealthy subjectsISRCTN13328584Kallyope (United States)36